The Pharmacy Times® Diabetes Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of chronic diseases that result in high blood glucose.
September 15th 2025
GLP-1 receptor agonists enhance glycemic control and weight management in youth with type 2 diabetes (T2D) and obesity, while safety concerns persist.
Empagliflozin Slows Renal Disease Progression in Type 2 Diabetes
June 23rd 2016New data from the EMPA-REG OUTCOME trial showed the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) significantly reduced the incidence of worsening kidney disease in type 2 diabetes patients.
Read More